Patents by Inventor Robin John Leatherbarrow

Robin John Leatherbarrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220411431
    Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).
    Type: Application
    Filed: July 27, 2022
    Publication date: December 29, 2022
    Applicant: Imperial College Innovations Limited
    Inventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
  • Patent number: 11466011
    Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: October 11, 2022
    Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
  • Publication number: 20200339586
    Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).
    Type: Application
    Filed: July 8, 2020
    Publication date: October 29, 2020
    Applicant: Imperial College Innovations Limited
    Inventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
  • Patent number: 10759804
    Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 1, 2020
    Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
  • Publication number: 20180370974
    Abstract: This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect, including protozoan infections (such as malaria and leishmaniasis), viral infections (such as human rhinovirus and HIV), and hyperproliferative disorders (such as B-cell lymphoma).
    Type: Application
    Filed: June 29, 2016
    Publication date: December 27, 2018
    Applicant: Imperial Innovations Limited
    Inventors: Andrew Simon Bell, Edward William Tate, Robin John Leatherbarrow, Jennie Ann Hutton, James Antony Brannigan
  • Patent number: 8664357
    Abstract: According to the present invention, there is provided a process for the preparation of a first compound selected from peptides, oligonucleotides and peptide nucleic acids. The process comprises synthesizing the first compound and then separating the first compound formed in step (i) from a second compound, which is a reaction by-product of the synthesis of the first compound and/or an excess of a reagent used for the synthesis of a first compound by a process of diafiltration. The membrane used for the diafiltration process is stable in organic solvents and provides a rejection for the first compound which is greater than the rejection for the second compound.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: March 4, 2014
    Assignee: Imperial Innovations Limited
    Inventors: Andrew Guy Livingston, Ludmila Georgieva Peeva, Sheyung Wang Jerry So, Renato Campos Vasconceles, Robin John Leatherbarrow, Edward William Tate, Piers Robert James Gaffney
  • Publication number: 20110245460
    Abstract: According to the present invention, there is provided a process for the preparation of a first compound selected from peptides, oligonucleotides and peptide nucleic acids. The process comprises synthesising the first compound and then separating the first compound formed in step (i) from a second compound, which is a reaction by-product of the synthesis of the first compound and/or an excess of a reagent used for the synthesis of a first compound by a process of diafiltration. The membrane used for the diafiltration process is stable in organic solvents and provides a rejection for the first compound which is greater than the rejection for the second compound.
    Type: Application
    Filed: August 7, 2009
    Publication date: October 6, 2011
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Andrew Guy Livingston, Ludmila Georgieva Peeva, Sheyung Wang Jerry So, Renato Campos Vasconceles, Robin John Leatherbarrow, Edward William Tate, Piers Robert James Gaffney